September 13, 2024Open Access

Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States

Key Points

Key points are not available for this paper at this time.

Abstract

Nivolumab, recently proven in a phase 3 clinical trial (CheckMate 901) to enhance survival when combined with gemcitabine-cisplatin for advanced urothelial carcinoma. This study aimed to assess its cost-effectiveness against gemcitabine-cisplatin alone, from US and Chinese payers' perspectives.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper

Cite This Study

Xiang et al. (Fri,) studied this question.

synapsesocial.com/papers/68e58a50b6db643587525c78 https://doi.org/https://doi.org/10.3389/fimmu.2024.1426024

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cost-Effectiveness of Osimertinib for EGFR Mutation–Positive Non–Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy2017 · 82 citations
2Cancer statistics, 20232023 · 16,704 citations
3Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score2023 · 25 citations
4Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021 · 112,778 citations
5Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis2020 · 227 citations

AIに質問

Bookmark

View Full Paper